Document Detail


The ketogenic diet as a treatment paradigm for diverse neurological disorders.
MedLine Citation:
PMID:  22509165     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Dietary and metabolic therapies have been attempted in a wide variety of neurological diseases, including epilepsy, headache, neurotrauma, Alzheimer disease, Parkinson disease, sleep disorders, brain cancer, autism, pain, and multiple sclerosis. The impetus for using various diets to treat - or at least ameliorate symptoms of - these disorders stems from both a lack of effectiveness of pharmacological therapies, and also the intrinsic appeal of implementing a more "natural" treatment. The enormous spectrum of pathophysiological mechanisms underlying the aforementioned diseases would suggest a degree of complexity that cannot be impacted universally by any single dietary treatment. Yet, it is conceivable that alterations in certain dietary constituents could affect the course and impact the outcome of these brain disorders. Further, it is possible that a final common neurometabolic pathway might be influenced by a variety of dietary interventions. The most notable example of a dietary treatment with proven efficacy against a neurological condition is the high-fat, low-carbohydrate ketogenic diet (KD) used in patients with medically intractable epilepsy. While the mechanisms through which the KD works remain unclear, there is now compelling evidence that its efficacy is likely related to the normalization of aberrant energy metabolism. The concept that many neurological conditions are linked pathophysiologically to energy dysregulation could well provide a common research and experimental therapeutics platform, from which the course of several neurological diseases could be favorably influenced by dietary means. Here we provide an overview of studies using the KD in a wide panoply of neurologic disorders in which neuroprotection is an essential component.
Authors:
Carl E Stafstrom; Jong M Rho
Related Documents :
20854335 - Harsh physical punishment as a specific childhood adversity linked to adult drinking co...
23339675 - Have the canmat bipolar guidelines transmogrified from do matter to can matter?
22275845 - A lifespan view of anxiety disorders.
24430335 - Treatment implications of high-resolution manometry findings: options for patients with...
15274955 - Obsessive compulsive disorder secondary to head injury.
24068375 - Unusual presentation of two chinese phenylketonuria sisters who were misdiagnosed for y...
Publication Detail:
Type:  Journal Article     Date:  2012-04-09
Journal Detail:
Title:  Frontiers in pharmacology     Volume:  3     ISSN:  1663-9812     ISO Abbreviation:  Front Pharmacol     Publication Date:  2012  
Date Detail:
Created Date:  2012-04-17     Completed Date:  2012-10-02     Revised Date:  2013-08-13    
Medline Journal Info:
Nlm Unique ID:  101548923     Medline TA:  Front Pharmacol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  59     Citation Subset:  -    
Affiliation:
Department of Neurology, University of Wisconsin Madison, WI, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quality Difference Study of Six Varieties of Ganoderma lucidum with Different Origins.
Next Document:  Molecular pathways of notch signaling in vascular smooth muscle cells.